This Colgate-Palmolive Analyst Is Turning Bullish On Heels Of CBD, Dental Pain Study

Shares of Colgate-Palmolive Company (NYSE: CL) have been in focus after a new study revealed that CBD, a cannabis compound, was safe for managing acute dental pain.

The company is now likely to generate 4.5% year-on-year organic sales growth in fiscal 2024, versus earlier expectations of 3.6%, according to BofA Securities.

The Colgate-Palmolive Analyst: Bryan Spillane upgraded the rating for Colgate-Palmolive from Neutral to Buy, while raising the price target from $75 to $90.

The Colgate-Palmolive Thesis: The company could generate growth higher than its long-term targets over the next 12 months, which would be a catalyst for its stock, Spillane said in the upgrade note.

Check out other analyst stock ratings.

The analyst listed the key drivers for fiscal 2024 sales and earnings upside as:

• “US volume and markets share turning positive driven by growth in non-measured channels, marketing and merchandising investments, new products and easier comparisons.”
• Growth in emerging markets being above average, “helped by continued pricing in Latin America, strong growth in India and broad market share improvement in oral care.”
• “Margin expansion as price continues to keep up with costs, pet acquisition built in the base.”

CL Price Action: Shares of Colgate-Palmolive had risen by 0.27% to $76.48 at the time of publication on Friday.

Image: Shutterstock